$XBI $118.69 -2.4%
Covid Updates
$SRNE -1.8% Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern. source
Pipeline Updates
$FATE -5.9% Fate Therapeutics Announces Positive Interim Clinical Data from its FT596 and FT516 Off-the-shelf, iPSC-derived NK Cell Programs for B-cell Lymphoma. source
$KDMN 0% Kadmon Announces U.S. Availability of REZUROCK™ (belumosudil) for the Treatment of Patients with Chronic Graft-Versus-Host Disease (cGVHD). source
$SRNE-1.8% Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives. source
$LTRN -5.4% Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration. source
$JAGX -0.9% Jaguar Health Subsidiary Napo Pharmaceuticals Signs License Agreement with its Italian Subsidiary, Napo EU S.p.A., to Develop and Commercialize Crofelemer and Lechlemer in Europe. source
$ZEAL -0.2% Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome. source
$CYDY +4.7% CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation. source
$CYTK -0.8% Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA. source
$PSTV -0.8% Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial. source
$ADAG -1.7% Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab). source
$IMPL -17.4% On 8/16 IMPEL NEUROPHARMA ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE. source
Financial Updates
$IMAB -15.8% I-Mab Announces Establishment of Environmental, Social and Governance Committee. source
$OTIC -14.1% Otonomy Appoints Jill Broadfoot to Board of Directors. source
Posted by FS
Comments